Abivax SA.
ABVX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Abivax SA is a biotechnology company focused on developing therapies for chronic inflammatory diseases, viral diseases, and cancer. Their lead product candidate is obefazimod, an oral small molecule in Phase 3 clinical development for the treatment of ulcerative colitis. They also have other program...Show More
Better Health for All
20
Abivax's core business is developing therapies for chronic inflammatory diseases, with its lead candidate, obefazimod, showing significant improvements in Phase 2b trials for ulcerative colitis, including 53% clinical remission and 82% clinical response after two years.
1
The company is currently in Phase 3 trials for obefazimod for UC and Phase 2b for Crohn's disease, indicating its entire business is devoted to health improvement.
2
The safety record for obefazimod is strong, with no new adverse safety signals observed in 1,074 patients treated up to five years.
3
The company's R&D expenses increased significantly to EUR 146.5M in 2024 from EUR 103.2M in 2023, representing 92% of its total operating expenses in 2024 (EUR 159.4M).
4
Abivax also initiated a Phase 2b/3 clinical trial for ABX464 (obefazimod) for COVID-19, demonstrating a direct response to a global health crisis.
5
Clinical trials are randomized, double-blind, and placebo-controlled with independent review.
6
However, the company's risk transparency is limited, as specific health risk disclosures or comprehensive benefit and risk data are not publicly available in the provided articles.
Fair Money & Economic Opportunity
0
Abivax SA is a biotechnology company focused on developing therapies, not a financial institution.
1
The company's core business involves research and development of medical treatments.
2
Therefore, it does not offer lending, deposit, or other financial services to consumers.
3
As a result, all Key Performance Indicators (KPIs) related to financial products, services, customer data, lending practices, or financial literacy initiatives are not applicable to its operations.
Fair Pay & Worker Respect
0
No specific, concrete data points were provided across the articles for any of the KPIs related to Fair Pay & Worker Respect. Information regarding living wage coverage, CEO to median employee pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage was not found.
1
While CEO compensation was mentioned, median employee compensation was not, preventing the calculation of the CEO to median pay ratio.
2
Mentions of staff representation or contractors did not include the necessary quantitative percentages for scoring.
3
Fair Trade & Ethical Sourcing
0
The provided article, Abivax SA's Privacy Policy, does not contain any information or quantitative data related to fair trade and ethical sourcing practices, supplier audits, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in contracts, materials risk index, or supplier diversity spend.
1
Therefore, no assessment can be made against the specified KPIs.
Honest & Fair Business
0
No specific, concrete evidence was found in the provided article to assess Abivax SA against any of the 'Honest & Fair Business' KPIs. The article mentions an 'independent board member'
1
but does not provide a quantitative percentage of board members free from material conflicts of interest, nor does it offer data for regulatory fines, transparency index scores, financial restatements, or other defined metrics.
Kind to Animals
-20
The company states that preclinical animal trials are performed to demonstrate product safety and efficacy, and that preclinical animal studies and human clinical trials are indispensable for obtaining marketing authorization for its products.
1
This indicates a reliance on animal testing as a standard practice for regulatory compliance, with no evidence of prohibiting discretionary testing or actively seeking alternatives.
No War, No Weapons
0
The provided articles, including confidential draft registration statements, ESG risk assessments, and company R&D updates, explicitly state that no specific or quantitative data relevant to Abivax SA (ABVX.US)'s involvement in arms contracts, dual-use technology, sales to embargoed regimes, peacebuilding investments, or any other metrics related to the 'No War, No Weapons' value is available.
1
One article referenced a European entity (2X10.DU) with 'None' or 'No' responses for categories like 'Controversial Weapons' and 'Military Contracting,' but this information is not applicable to ABVX.US.
2
Consequently, no KPIs can be scored based on the evidence provided.
Planet-Friendly Business
0
The provided article does not contain any specific, quantitative data related to planet-friendly business practices, including emissions, renewable energy, water use, waste diversion, or environmental compliance.
1
Therefore, no assessment can be made against the defined KPIs.
Respect for Cultures & Communities
0
No evidence available to assess Abivax SA on Respect for Cultures & Communities.
Safe & Smart Tech
0
Abivax SA's privacy policy describes user rights to access, correct, delete, and port data.
1
The company also states its compliance with GDPR.
2
Zero Waste & Sustainable Products
0
The provided article focuses on Abivax SA's overall ESG risk rating and peer comparisons, noting a 'High' ESG risk rating and 'Weak' ESG management.
1
However, it explicitly states that no quantitative data related to waste, sustainability, or zero-waste initiatives is provided.
2
Therefore, there is no specific evidence to assess the company against any of the 'Zero Waste & Sustainable Products' KPIs.